JP2019534277A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019534277A5 JP2019534277A5 JP2019520869A JP2019520869A JP2019534277A5 JP 2019534277 A5 JP2019534277 A5 JP 2019534277A5 JP 2019520869 A JP2019520869 A JP 2019520869A JP 2019520869 A JP2019520869 A JP 2019520869A JP 2019534277 A5 JP2019534277 A5 JP 2019534277A5
- Authority
- JP
- Japan
- Prior art keywords
- domain
- amino acid
- acid sequence
- sequence
- antibody construct
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 112
- 239000000427 antigen Substances 0.000 claims description 54
- 102000036639 antigens Human genes 0.000 claims description 54
- 108091007433 antigens Proteins 0.000 claims description 54
- 230000003993 interaction Effects 0.000 claims description 48
- 229920001184 polypeptide Polymers 0.000 claims description 48
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 48
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 48
- 230000035772 mutation Effects 0.000 claims description 44
- 102100035971 Molybdopterin molybdenumtransferase Human genes 0.000 claims description 23
- 101710119577 Molybdopterin molybdenumtransferase Proteins 0.000 claims description 23
- 238000012986 modification Methods 0.000 claims description 17
- 230000004048 modification Effects 0.000 claims description 17
- 210000004899 c-terminal region Anatomy 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022162426A JP7591015B2 (ja) | 2016-10-19 | 2022-10-07 | 抗体構築物 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662410054P | 2016-10-19 | 2016-10-19 | |
| US62/410,054 | 2016-10-19 | ||
| US201762549894P | 2017-08-24 | 2017-08-24 | |
| US62/549,894 | 2017-08-24 | ||
| US201762555498P | 2017-09-07 | 2017-09-07 | |
| US62/555,498 | 2017-09-07 | ||
| PCT/US2017/057268 WO2018075692A2 (en) | 2016-10-19 | 2017-10-18 | Antibody constructs |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022162426A Division JP7591015B2 (ja) | 2016-10-19 | 2022-10-07 | 抗体構築物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019534277A JP2019534277A (ja) | 2019-11-28 |
| JP2019534277A5 true JP2019534277A5 (OSRAM) | 2020-11-26 |
| JP7261158B2 JP7261158B2 (ja) | 2023-04-19 |
Family
ID=60452719
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019520869A Active JP7261158B2 (ja) | 2016-10-19 | 2017-10-18 | 抗体構築物 |
| JP2022162426A Active JP7591015B2 (ja) | 2016-10-19 | 2022-10-07 | 抗体構築物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022162426A Active JP7591015B2 (ja) | 2016-10-19 | 2022-10-07 | 抗体構築物 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20180118811A1 (OSRAM) |
| EP (1) | EP3529269B1 (OSRAM) |
| JP (2) | JP7261158B2 (OSRAM) |
| KR (3) | KR20240000650A (OSRAM) |
| CN (3) | CN118359705A (OSRAM) |
| AU (1) | AU2017345454B2 (OSRAM) |
| CA (1) | CA3041254A1 (OSRAM) |
| IL (1) | IL266143A (OSRAM) |
| MX (1) | MX421186B (OSRAM) |
| WO (1) | WO2018075692A2 (OSRAM) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20211273T1 (hr) | 2014-11-26 | 2021-11-12 | Xencor, Inc. | Heterodimerna protutijela koja vežu cd3 i cd20 |
| JP7058219B2 (ja) | 2015-12-07 | 2022-04-21 | ゼンコア インコーポレイテッド | Ｃｄ３及びｐｓｍａに結合するヘテロ二量体抗体 |
| FI3468586T3 (fi) | 2016-06-14 | 2024-10-29 | Xencor Inc | Bispesifisiä immuuniaktivaatiota vapauttavia vasta-aineita |
| CA3041254A1 (en) * | 2016-10-19 | 2018-04-26 | Invenra Inc. | Antibody constructs |
| WO2019183406A1 (en) * | 2018-03-21 | 2019-09-26 | Invenra Inc. | Multispecific antibody purification with ch1 resin |
| SG11202009036YA (en) | 2018-03-30 | 2020-10-29 | Merus Nv | Multivalent antibody |
| US20210163594A1 (en) * | 2018-04-17 | 2021-06-03 | Invenra Inc. | Binding molecules |
| MX2020010881A (es) | 2018-04-18 | 2020-11-09 | Exelixis Inc | Construcciones de anticuerpos anti-ror. |
| JP7193628B2 (ja) * | 2018-07-06 | 2022-12-20 | 北京天成新脉生物技▲術▼有限公司 | 低ａｄｃｃ／ｃｄｃ機能性モノクローナル抗体、及びその調製方法と使用 |
| EP3830129A4 (en) * | 2018-07-30 | 2022-05-04 | Invenra, Inc. | MULTISPECIFIC TREG-BINDING MOLECULES |
| BR112021006784A2 (pt) * | 2018-10-10 | 2021-09-21 | Zymeworks Inc. | Construtos de anticorpo que se ligam a 4-1bb e antígenos associados a tumor e usos dos mesmos |
| BR112021012338A2 (pt) | 2018-12-24 | 2021-09-14 | Sanofi | Proteínas de ligação multiespecíficas com domínios fab mutantes |
| EP4077374A4 (en) * | 2019-12-20 | 2023-12-27 | Kisoji Biotechnology Inc. | POLYPEPTIDES, PROTEIN COMPLEXES AND ASSOCIATED PRODUCTION PROCESS |
| CA3168444A1 (en) * | 2020-02-20 | 2021-08-26 | Win Therapeutics, Inc. | Bispecific gd2 and b7h2 binding molecules and methods of use |
| US12312418B2 (en) * | 2020-12-10 | 2025-05-27 | Invenra Inc. | Orthogonal mutations for heterodimerization |
| WO2023245021A2 (en) * | 2022-06-14 | 2023-12-21 | Invenra Inc. | Multispecific binding agents that target cd25 and/or ctla4 and uses thereof |
| TW202506726A (zh) * | 2023-04-07 | 2025-02-16 | 美商麥迪紐有限責任公司 | 雙特異性工程化抗體 |
| WO2025129132A1 (en) * | 2023-12-14 | 2025-06-19 | Invenra Inc. | Multispecific binding agents that target ctla4 and/or cd25 and uses thereof |
Family Cites Families (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8905551D0 (en) * | 1989-03-10 | 1989-04-19 | Unilever Plc | Detergent compositions |
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| EP0940468A1 (en) | 1991-06-14 | 1999-09-08 | Genentech, Inc. | Humanized antibody variable domain |
| US5773001A (en) | 1994-06-03 | 1998-06-30 | American Cyanamid Company | Conjugates of methyltrithio antitumor agents and intermediates for their synthesis |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US6685940B2 (en) | 1995-07-27 | 2004-02-03 | Genentech, Inc. | Protein formulation |
| US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
| US7097840B2 (en) | 2000-03-16 | 2006-08-29 | Genentech, Inc. | Methods of treatment using anti-ErbB antibody-maytansinoid conjugates |
| SI2357006T1 (sl) | 2002-07-31 | 2016-01-29 | Seattle Genetics, Inc. | Konjugati zdravil in njihova uporaba za zdravljenje raka, avtoimunske bolezni ali infekcijske bolezni |
| DK2335725T3 (en) | 2003-04-04 | 2017-01-23 | Genentech Inc | Highly concentrated antibody and protein formulations |
| US8088387B2 (en) | 2003-10-10 | 2012-01-03 | Immunogen Inc. | Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates |
| BR122018071808B8 (pt) | 2003-11-06 | 2020-06-30 | Seattle Genetics Inc | conjugado |
| US20050175619A1 (en) | 2004-02-05 | 2005-08-11 | Robert Duffy | Methods of producing antibody conjugates |
| AU2005216251B2 (en) | 2004-02-23 | 2011-03-10 | Genentech, Inc. | Heterocyclic self-immolative linkers and conjugates |
| EP1817341A2 (en) | 2004-11-29 | 2007-08-15 | Seattle Genetics, Inc. | Engineered antibodies and immunoconjugates |
| GB0514779D0 (en) | 2005-07-19 | 2005-08-24 | Celltech R&D Ltd | Biological products |
| WO2007030642A2 (en) | 2005-09-07 | 2007-03-15 | Medimmune, Inc. | Toxin conjugated eph receptor antibodies |
| WO2007103288A2 (en) | 2006-03-02 | 2007-09-13 | Seattle Genetics, Inc. | Engineered antibody drug conjugates |
| EP2217283A2 (en) | 2007-11-28 | 2010-08-18 | Mersana Therapeutics, Inc. | Biocompatible biodegradable fumagillin analog conjugates |
| KR20150080038A (ko) | 2007-11-30 | 2015-07-08 | 애브비 바이오테크놀로지 리미티드 | 단백질 제형 및 이의 제조방법 |
| US8242247B2 (en) | 2007-12-21 | 2012-08-14 | Hoffmann-La Roche Inc. | Bivalent, bispecific antibodies |
| ES2563027T3 (es) | 2008-01-07 | 2016-03-10 | Amgen Inc. | Método para fabricación de moléculas heterodímeras Fc de anticuerpos utilizando efectos de conducción electrostática |
| CL2009002167A1 (es) | 2008-12-10 | 2010-10-15 | Mersana Therapeutics Inc | Formulacion farmaceutica para administracion endovenosa que comprende un compuesto derivado de conjugados de camptotecina-polimero biocompatibles y biodegradables, un agente de estabilizacion, uno o varios tampones y un tensoactivo, util para el tratamiento del cancer. |
| CA2762877A1 (en) | 2009-05-28 | 2010-12-02 | Mersana Therapeutics, Inc. | Polyal drug conjugates comprising variable rate-releasing linkers |
| RS58810B1 (sr) | 2009-06-03 | 2019-07-31 | Immunogen Inc | Metodi konjugacije |
| BR112012021576A2 (pt) | 2010-02-26 | 2016-10-25 | Novo Nordisk As | composições estáveis contendo anticorpo. |
| US8821865B2 (en) | 2010-11-11 | 2014-09-02 | Abbvie Biotechnology Ltd. | High concentration anti-TNFα antibody liquid formulations |
| RU2620071C2 (ru) * | 2010-11-17 | 2017-05-22 | Чугаи Сеияку Кабушики Каиша | Мультиспецифическая связывающая антиген молекула, которая обладает альтернативной функцией к функции фактора свертывания крови viii |
| SG193022A1 (en) | 2011-03-10 | 2013-10-30 | Eisai R&D Man Co Ltd | Method for screening for compound capable of enhancing or inhibiting oatp1b1 transport activity, and method for determining expression level of oatp1b1 |
| EP2717916B1 (en) | 2011-06-10 | 2017-03-08 | Mersana Therapeutics, Inc. | Protein-polymer-drug conjugates |
| US8790651B2 (en) * | 2011-07-21 | 2014-07-29 | Zoetis Llc | Interleukin-31 monoclonal antibody |
| CA2843158A1 (en) * | 2011-08-26 | 2013-03-07 | Merrimack Pharmaceuticals, Inc. | Tandem fc bispecific antibodies |
| PL2794905T3 (pl) | 2011-12-20 | 2020-11-02 | Medimmune, Llc | Zmodyfikowane polipeptydy dla rusztowań przeciwciał dwuswoistych |
| CN120383672A (zh) * | 2012-04-20 | 2025-07-29 | 美勒斯公司 | 用于产生免疫球蛋白样分子的方法和手段 |
| KR102557309B1 (ko) | 2012-05-15 | 2023-07-20 | 씨젠 인크. | 자가-안정화 링커 접합체 |
| US9216219B2 (en) | 2012-06-12 | 2015-12-22 | Novartis Ag | Anti-BAFFR antibody formulation |
| US20140017265A1 (en) | 2012-07-05 | 2014-01-16 | Mersana Therapeutics, Inc. | Terminally Modified Polymers and Conjugates Thereof |
| MX2015004668A (es) | 2012-10-25 | 2015-07-23 | Medimmune Llc | Formulacion estable de anticuerpos de baja viscosidad. |
| AU2013359506B2 (en) | 2012-12-10 | 2018-05-24 | Mersana Therapeutics, Inc. | Protein-polymer-drug conjugates |
| EP2931316B1 (en) | 2012-12-12 | 2019-02-20 | Mersana Therapeutics, Inc. | Hydroxyl-polymer-drug-protein conjugates |
| US20160022829A1 (en) | 2013-03-14 | 2016-01-28 | Mersana Therapeutics, Inc. | Tubulysin compounds and conjugates thereof |
| EA032231B1 (ru) | 2013-10-11 | 2019-04-30 | Мерсана Терапьютикс, Инк. | Конъюгаты белок-полимер-лекарственное средство |
| NZ758050A (en) | 2013-10-15 | 2024-03-22 | Seagen Inc | Pegylated drug-linkers for improved ligand-drug conjugate pharmacokinetics |
| US11116847B2 (en) | 2013-12-19 | 2021-09-14 | Seagen Inc. | Methylene carbamate linkers for use with targeted-drug conjugates |
| IL309933A (en) | 2014-02-17 | 2024-03-01 | Seagen Inc | Hydrophilic antibody-drug conjugates |
| UA117289C2 (uk) * | 2014-04-02 | 2018-07-10 | Ф. Хоффманн-Ля Рош Аг | Мультиспецифічне антитіло |
| CA2942150A1 (en) | 2014-04-07 | 2015-10-15 | Seattle Genetics, Inc. | Stable formulations for anti-cd19 antibodies and antibody-drug conjugates |
| US9808528B2 (en) | 2014-06-18 | 2017-11-07 | Mersana Therapeutics, Inc. | Protein-polymer-drug conjugates and methods of using same |
| TWI551060B (zh) * | 2014-09-24 | 2016-09-21 | 衡宇科技股份有限公司 | Ｂｃｈ解碼方法及其解碼器 |
| JP6904902B2 (ja) * | 2014-12-05 | 2021-07-21 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ | ドメイン交換抗体 |
| WO2016180941A1 (en) | 2015-05-13 | 2016-11-17 | Sanofi | Liquid compositions for anti-cd19 antibody-drug conjugates |
| EP3653628B1 (en) | 2015-07-21 | 2022-09-14 | ImmunoGen, Inc. | Methods of preparing cytotoxic benzodiazepine derivatives |
| EP3411077A1 (en) | 2016-02-05 | 2018-12-12 | ImmunoGen, Inc. | Efficient process for preparing cell-binding agent-cytotoxic agent conjugates |
| BR112018068461A2 (pt) | 2016-03-15 | 2019-01-22 | Mersana Therapeutics Inc | conjugado, composição farmacêutica, métodos para preparação de um conjugado e para alívio de um sintoma de um câncer. |
| JP7073266B2 (ja) | 2016-03-25 | 2022-05-23 | シージェン インコーポレイテッド | Ｐｅｇ化薬物リンカー及びその中間体を調製するためのプロセス |
| EP3241531A1 (en) * | 2016-05-04 | 2017-11-08 | noonee AG | Leg unit for a wearable sitting posture assisting device |
| CA3041254A1 (en) * | 2016-10-19 | 2018-04-26 | Invenra Inc. | Antibody constructs |
| WO2019204398A1 (en) * | 2018-04-17 | 2019-10-24 | Invenra Inc. | Trivalent trispecific antibody constructs |
| US20210163594A1 (en) * | 2018-04-17 | 2021-06-03 | Invenra Inc. | Binding molecules |
| MX2020010881A (es) * | 2018-04-18 | 2020-11-09 | Exelixis Inc | Construcciones de anticuerpos anti-ror. |
| EP3830129A4 (en) * | 2018-07-30 | 2022-05-04 | Invenra, Inc. | MULTISPECIFIC TREG-BINDING MOLECULES |
| WO2021145946A1 (en) * | 2020-01-13 | 2021-07-22 | Invenra Inc. | Multispecific treg binding molecules |
-
2017
- 2017-10-18 CA CA3041254A patent/CA3041254A1/en active Pending
- 2017-10-18 AU AU2017345454A patent/AU2017345454B2/en active Active
- 2017-10-18 CN CN202410343134.7A patent/CN118359705A/zh active Pending
- 2017-10-18 WO PCT/US2017/057268 patent/WO2018075692A2/en not_active Ceased
- 2017-10-18 JP JP2019520869A patent/JP7261158B2/ja active Active
- 2017-10-18 CN CN202410332902.9A patent/CN118359704A/zh active Pending
- 2017-10-18 MX MX2019004690A patent/MX421186B/es unknown
- 2017-10-18 KR KR1020237043908A patent/KR20240000650A/ko active Pending
- 2017-10-18 US US15/787,640 patent/US20180118811A1/en not_active Abandoned
- 2017-10-18 KR KR1020257008855A patent/KR20250044934A/ko active Pending
- 2017-10-18 EP EP17804323.8A patent/EP3529269B1/en active Active
- 2017-10-18 KR KR1020197013738A patent/KR102617264B1/ko active Active
- 2017-10-18 CN CN201780078920.7A patent/CN110177805B/zh active Active
-
2019
- 2019-04-18 IL IL266143A patent/IL266143A/en unknown
-
2022
- 2022-10-07 JP JP2022162426A patent/JP7591015B2/ja active Active
- 2022-11-15 US US18/055,720 patent/US20240043502A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019534277A5 (OSRAM) | ||
| JP2018537966A5 (OSRAM) | ||
| JP2020531438A5 (ja) | Ｎｋｇ２ｄ、ｃｄ１６、およびｈｌａ−ｅに結合するタンパク質 | |
| JP2023085476A5 (OSRAM) | ||
| IL274071B1 (en) | Method for in vivo generation of multispecific antibodies from monospecific antibodies | |
| JP2017504578A5 (OSRAM) | ||
| JP2017504577A5 (OSRAM) | ||
| JP2016536322A5 (OSRAM) | ||
| JP2020519643A5 (OSRAM) | ||
| JP2016527314A5 (OSRAM) | ||
| JP2020525032A5 (OSRAM) | ||
| JP2019536430A5 (OSRAM) | ||
| JP2019525738A5 (OSRAM) | ||
| JP2020508997A5 (OSRAM) | ||
| JP2024167313A5 (OSRAM) | ||
| RU2016106577A (ru) | САЙТЫ АНТИТЕЛ, СПЕЦИФИЧНО СВЯЗЫВАЮЩИЕ EGFRvIII | |
| JP2017528117A5 (OSRAM) | ||
| FI3392276T3 (fi) | Heterodimeerimolekyyli, joka perustuu rakenteelliseen CH3-domeeniin, sekä menetelmä sen valmistamiseksi ja sen käyttö | |
| JP2017529067A5 (OSRAM) | ||
| JP2018517431A5 (OSRAM) | ||
| JP2015146822A5 (OSRAM) | ||
| HRP20211528T1 (hr) | Trispecifični i/ili trovalentni vezujući proteini za prevenciju ili liječenje hiv infekcije | |
| JP2017533694A5 (OSRAM) | ||
| JP2018522541A5 (OSRAM) | ||
| JP2013545455A5 (OSRAM) |